Evidence map›Paper›PMID 36232851›Full record

ArticleInternational journal of molecular sciences2022

A Previously Unrecognized Molecular Landscape of Lynch Syndrome in the Mexican Population.

Alejandra Padua-Bracho, José A Velázquez-Aragón, Verónica Fragoso-Ontiveros, Paulina María Nuñez-Martínez, María de la Luz Mejía Aguayo, Yuliana Sánchez-Contreras, Miguel Angel Ramirez-Otero, Marcela Angélica De la Fuente-Hernández, Silvia Vidal-Millán, Talia Wegman-Ostrosky and 4 more

Open access · goldAbstract read
In one paragraph

Article in International journal of molecular sciences, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
0.9field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 7 citations in OpenAlex.

  1. Long non-coding RNAs in exercise: the hidden regulators of adaptation.Pflugers Archiv : European journal of physiology · 2026
    Review
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 3 institutions in 1 country.

Alejandra Padua-BrachoHereditary Cancer Clinic, National Cancer Institute, Mexico City 14080, Mexico.
José A Velázquez-AragónExperimental Oncology Laboratory, National Pediatric Institute, Mexico City 04530, Mexico.ORCID 0000-0002-3617-8148
Verónica Fragoso-OntiverosHereditary Cancer Clinic, National Cancer Institute, Mexico City 14080, Mexico.
Paulina María Nuñez-MartínezHereditary Cancer Clinic, National Cancer Institute, Mexico City 14080, Mexico.ORCID 0000-0002-3315-1185
María de la Luz Mejía AguayoHereditary Cancer Clinic, National Cancer Institute, Mexico City 14080, Mexico.
Yuliana Sánchez-ContrerasHereditary Cancer Clinic, National Cancer Institute, Mexico City 14080, Mexico.
Miguel Angel Ramirez-OteroHereditary Cancer Clinic, National Cancer Institute, Mexico City 14080, Mexico.ORCID 0000-0001-8428-1150
Marcela Angélica De la Fuente-HernándezHereditary Cancer Clinic, National Cancer Institute, Mexico City 14080, Mexico.
Silvia Vidal-MillánHereditary Cancer Clinic, National Cancer Institute, Mexico City 14080, Mexico.
Talia Wegman-OstroskyBasic Research Sub Direction, National Cancer Institute, Mexico City 14080, Mexico.ORCID 0000-0002-3207-6697
Abraham Pedroza-TorresHereditary Cancer Clinic, National Cancer Institute, Mexico City 14080, Mexico.ORCID 0000-0001-7857-3464
Cristian Arriaga-CanonBasic Research Sub Direction, National Cancer Institute, Mexico City 14080, Mexico.
Luis A Herrera-MontalvoGeneral Management, National Institute of Genomic Medicine, Mexico City 14610, Mexico.ORCID 0000-0003-3998-9306
Rosa Maria Alvarez-GómezHereditary Cancer Clinic, National Cancer Institute, Mexico City 14080, Mexico.
Instituto Nacional de Cancerología · MXTecnológico Nacional de México · MXNational Institute of Genomic Medicine · MX

Funding

Consejo Nacional de Ciencia y Tecnología FOSISS SALUD-2018-02-A3-S-39248A3-S-39248
6 · The paper itself

Abstract

Lynch syndrome (LS) is the main hereditary colorectal cancer syndrome. There have been few reports regarding the clinical and molecular characteristics of LS patients in Latin America; this is particularly true in the Mexican population, where no information is available. The present study aims to describe the clinical and molecular spectrum of variants in a cohort of patients diagnosed with LS in Mexico. We present a retrospective analysis of 412 patients with suspected LS, whose main site of cancer diagnosis was the colon (58.25%), followed by the endometrium (18.93%). Next-generation sequencing analysis, with an extensive multigene panel, showed that 27.1% (112/414) had a variant in one of the genes of the mismatch repair pathway (MMR); 30.4% (126/414) had a variant in non-MMR genes such as

Indexed as

Colorectal Neoplasms, Hereditary NonpolyposisDNA-Binding ProteinsDNA Mismatch RepairFemaleGerm-Line MutationHumansImmune Checkpoint InhibitorsMexicoMutS Homolog 2 ProteinRetrospective StudiesDNA-Binding ProteinsImmune Checkpoint InhibitorsMutS Homolog 2 ProteinEPCAMLynch syndromeMLH1MSH2MSH6mutationspathogenic variantsPMS2variants of uncertain significance

Identifiers

PMID36232851
PMCPMC9569652
OpenAlexW4298146344

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.